SciClone Pharmaceuticals announced that in the annual competition sponsored by the Tag and Label Manufacturers Institute (TLMI), its newly created anti-counterfeiting Pharma-Comb Void label for ZADAXIN has won the prestigious “Innovator Award.”
Created for SciClone by Schreiner MediPharm, a developer and manufacturer of pharmaceutical specialty labels based in Germany, the ZADAXIN label has been designed based on an innovative multipart concept to ensure product safety and security, as well as to counteract the illegal practice of refilling previously used medicine vials.
The serious problem of drug counterfeiting is a challenge facing the pharmaceutical industry, public health and regulatory authorities throughout the world. This problem is also a threat to patient safety, compromising the supply and efficacy of medical interventions as well as damaging the commercial viability of important drug therapies. Committed to ensuring patient safety and security for all its marketed products, SciClone intends to continue implementing an aggressive anti-counterfeiting strategy for ZADAXIN, working collaboratively with agencies and health authorities to fight the crime of illegal medication trafficking.
During its initial use, the ZADAXIN Pharma-Comb Void label is designed to be functionally destroyed. The inscriptions “Opened” and “Used” appear in two indicator fields when the label’s tear strip – which also encircles the closure cap – is removed. This design is intended to make it virtually impossible to reuse a glass container with an original label without the fraudulence being detected. The company believes that its Pharma-Comb Void label overcomes the limitations of conventional vials, which can be filled a second time and sold, undetected, as originals – even when equipped with overt security features like holograms or color-shifting inks. The new ZADAXIN label has been created to counteract this practice; it also offers a valuable-added benefit for healthcare professionals, which is that a detachable part is released when the label is opened, serving to mark the syringe accordingly.
China-focused but based in the United States, SciClone Pharmaceuticals is a specialty pharmaceutical company with a portfolio of therapies for oncology, infectious diseases and cardiovascular, urological, respiratory and central nervous system disorders. The company’s ZADAXIN (thymalfasin) has been approved in more than 30 countries and can be used to treat hepatitis B, hepatitis C and certain cancers, as well being used as a vaccine adjuvant, according to the legal regulatory approvals. In addition to ZADAXIN, SciClone also markets around 14 products in China, mostly partnered, including Depakine, Tritace, Stilnox (marketed as Ambien in the U.S.) and Aggrastat. The company is additionally pursuing the registration of various other therapeutic products in China.
For more information, visit the company’s Web site at www.sciclone.com
Let us hear your thoughts below: